JPS6247189B2 - - Google Patents
Info
- Publication number
- JPS6247189B2 JPS6247189B2 JP6759481A JP6759481A JPS6247189B2 JP S6247189 B2 JPS6247189 B2 JP S6247189B2 JP 6759481 A JP6759481 A JP 6759481A JP 6759481 A JP6759481 A JP 6759481A JP S6247189 B2 JPS6247189 B2 JP S6247189B2
- Authority
- JP
- Japan
- Prior art keywords
- camptothecin
- aldehyde
- group
- mmol
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 150000003839 salts Chemical group 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 9
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 5
- 229940127093 camptothecin Drugs 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- -1 aldehyde hydrazone Chemical class 0.000 description 4
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- YXAJNVUUZOLUSA-UHFFFAOYSA-N acetohydrazide;pyridin-1-ium;chloride Chemical compound [Cl-].CC(=O)NN.C1=CC=[NH+]C=C1 YXAJNVUUZOLUSA-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KVYKDNGUEZRPGJ-UHFFFAOYSA-N 1-Aminohydantoin Chemical compound NN1CC(=O)NC1=O KVYKDNGUEZRPGJ-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- MIQKQAFRWSMHEI-UHFFFAOYSA-N 4-methylpiperazin-1-amine;dihydrochloride Chemical compound Cl.Cl.CN1CCN(N)CC1 MIQKQAFRWSMHEI-UHFFFAOYSA-N 0.000 description 1
- KMVPXBDOWDXXEN-UHFFFAOYSA-N 4-nitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1 KMVPXBDOWDXXEN-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- AVKHCKXGKPAGEI-UHFFFAOYSA-N Phenicarbazide Chemical compound NC(=O)NNC1=CC=CC=C1 AVKHCKXGKPAGEI-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ADTNAQKEGWXKCL-UHFFFAOYSA-N acetohydrazide;pyridine Chemical compound CC(=O)NN.C1=CC=NC=C1 ADTNAQKEGWXKCL-UHFFFAOYSA-N 0.000 description 1
- NLTQZUCBHQFOIO-UHFFFAOYSA-N acetohydrazide;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.CC(=O)NN NLTQZUCBHQFOIO-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001206 phenicarbazide Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6759481A JPS57185285A (en) | 1981-05-07 | 1981-05-07 | Novel camptothecin derivative |
US06/336,494 US4399276A (en) | 1981-01-09 | 1981-12-31 | 7-Substituted camptothecin derivatives |
CA000393558A CA1177487A (en) | 1981-01-09 | 1982-01-04 | 7-substituted camptothecin derivatives and process for preparing same |
DE8282300104T DE3265308D1 (en) | 1981-01-09 | 1982-01-08 | 7-substituted camptothecin derivatives and process for their preparation |
EP82300104A EP0056692B1 (en) | 1981-01-09 | 1982-01-08 | 7-substituted camptothecin derivatives and process for their preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6759481A JPS57185285A (en) | 1981-05-07 | 1981-05-07 | Novel camptothecin derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57185285A JPS57185285A (en) | 1982-11-15 |
JPS6247189B2 true JPS6247189B2 (US06168655-20010102-C00055.png) | 1987-10-06 |
Family
ID=13349385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6759481A Granted JPS57185285A (en) | 1981-01-09 | 1981-05-07 | Novel camptothecin derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57185285A (US06168655-20010102-C00055.png) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0310590U (US06168655-20010102-C00055.png) * | 1989-06-16 | 1991-01-31 | ||
JPH0573991U (ja) * | 1992-03-12 | 1993-10-08 | 富士通株式会社 | モジュールカードの実装構造 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030344A1 (it) * | 2003-07-14 | 2005-01-15 | Ist Naz Stud Cura Dei Tumori | 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi. |
-
1981
- 1981-05-07 JP JP6759481A patent/JPS57185285A/ja active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0310590U (US06168655-20010102-C00055.png) * | 1989-06-16 | 1991-01-31 | ||
JPH0573991U (ja) * | 1992-03-12 | 1993-10-08 | 富士通株式会社 | モジュールカードの実装構造 |
Also Published As
Publication number | Publication date |
---|---|
JPS57185285A (en) | 1982-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4399276A (en) | 7-Substituted camptothecin derivatives | |
JP4663986B2 (ja) | フレデリカマイシン−誘導体 | |
CA2950300A1 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
BR112017006085B1 (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, uso do composto ou seu sal farmaceuticamente aceitável | |
BR112021013557A2 (pt) | Amidas de pirrolidina substituídas iii | |
JPH0730018B2 (ja) | 新規化合物の3−アミノ−2−オキソアゼチジン誘導体及びそれらの製造法 | |
JP3192027B2 (ja) | 2−ホルミルピリジンチオセミカルバゾン抗腫瘍剤 | |
US9266880B2 (en) | Substituted azaindazole compounds | |
JPH08337584A (ja) | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 | |
Zefirov et al. | Rearrangements and cyclizations—XVI: Ring-opening reactions of 1, 1-diacetylcyclopropane with hydrazine and hydroxylamine derivatives as the novel synthesis of β-X-ethyl substituted pyrazoles and isoxazoles | |
JPS6247189B2 (US06168655-20010102-C00055.png) | ||
JP3083544B2 (ja) | 心疾患を予防または治療する薬剤 | |
JPH029032B2 (US06168655-20010102-C00055.png) | ||
EP3421456A1 (en) | New route of synthesis for opicapone | |
US20120214846A1 (en) | Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators | |
JPS5890581A (ja) | 複素環式化合物、その製法及び同化合物を含有する抗高血圧作用性薬剤 | |
EP0099815A1 (fr) | Dérivés du pyridyl-3 alcoxy-(ou phénoxy- ou aralkyloxy-)5 pyrazole, procédé de préparation et application en thérapeutique | |
BR112021005793A2 (pt) | composto e processos para preparar um composto | |
Vaddiraju et al. | Synthesis and biological evaluation of novel ri, r2 substituted 2-(4-((2-(4-alkoxyphenyl)-5-methyloxazol-4-yl) methyl)-1-alkyl-5-methyl-1h-pyrazol-3-yloxy)-6-(hydroxymethyl) tetrahydro-2h-pyran-3, 4, 5-triol having anti diabetic activity | |
US20230286921A1 (en) | Method for Manufacturing Compound | |
US20120095055A1 (en) | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | |
CN108586436A (zh) | 一类含吲哚骨架的双酰肼类衍生物及其制备方法和应用 | |
JP3009716B2 (ja) | 新規なカンプトテシン誘導体 | |
JP2627441B2 (ja) | 1―アセトキシム―2―ニトロイミダゾール誘導体 | |
CN106699656A (zh) | 培氟沙星醛缩4‑芳基氨基硫脲类衍生物及其制备方法和应用 |